Results 141 to 150 of about 39,781 (168)

Letter to the editor: When do rare events become expected in HIV drug resistance? [PDF]

Euro Surveill
El-Khatib Z, Wessman M, Sönnerborg A, Fonager J, Zoufaly A, Leierer G, Assadian O, Benka B, Ndeikoundam Ngangro N, Kantor R.   +9 more
europepmc   +1 more source

Three-Year CD4/CD8 Ratio Recovery After Initiation of Dual Versus Triple Integrase Inhibitor-Based Therapy in Naïve Adults With HIV. [PDF]

Open Forum Infect Dis
Navarro-Soler R, García-Ruiz de Morales AG, Macías J, Sánchez-Villegas J, Blanco Arévalo JL, García Rosado D, Ocampo Hermida A, Gómez Ayerbe C, Moreno S, Martínez-Sanz J, Serrano-Villar S.   +10 more
europepmc   +1 more source

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro. [PDF]

Open Forum Infect Dis
Saladini F, Giannini A, Giammarino F, Antonova A, Ozhmegova E, Kaiser R, Dragoni F, Boccuto A, Vicenti I, Sönnerborg A, Bobkova M, Zazzi M.   +11 more
europepmc   +1 more source

Virological Failure and Mortality Among People Living with HIV Transitioned to Second- or Third-Line Antiretroviral Therapy in Rwanda: A Competing-Risks Survival Analysis of National Case-Based Surveillance Data, 2019-2025. [PDF]

Viruses
Rwibasira GN, Kwizera JC, Dzinamarira T, Karera S, Gaetan G, Tuyishime A, Remera E, Paris DH, Glass TR.   +8 more
europepmc   +1 more source

Systematic Literature Review and Meta-Analysis of INSTI-Based Antiretroviral Therapy Single- Versus Multiple-Tablet Regimens for the Treatment of HIV. [PDF]

Adv Ther
Tuzil J, Christoph MJ, Chen M, Lach K, Haloski K, Park S, Mordi U, Dudzic M, Zachry W.   +8 more
europepmc   +1 more source

Altered Lipid and Neurotransmitter Metabolism as Potential Mechanisms of Weight Gain in Women With HIV Initiating INSTIs in a Pilot Study. [PDF]

J Acquir Immune Defic Syndr
Alvarez JA, Teeny S, Yang CA, Mehta CC, Yang Q, Jones DP, Go YM, Sheth A, Ofotokun I, Ali MK, Ziegler TR, Lahiri CD.   +11 more
europepmc   +1 more source

Determinants of HIV-1 virologic suppression in HIV-associated tuberculosis in Brazil. [PDF]

Mem Inst Oswaldo Cruz
Ridolfi F, Amorim G, Haas DW, Arriaga M, Staats C, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Andrade BB, Sterling TR, Rolla VC, Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil Consortium, Benjamin A, Sant'Anna FM, Oliveira JG, Marin J, Rezende A, Carvalho AC, Rocha M, Nogueira B, Brito A, Spener R, Turner M.   +22 more
europepmc   +1 more source

Healthcare Utilization and Costs in People Living with HIV and Neuropsychiatric Disorders in the United States. [PDF]

Adv Ther
Fleming SP, Kamat S, Prajapati G, Chirikov V, Quan W, Bounthavong M.   +5 more
europepmc   +1 more source

Gut Microbiota Alterations in People Living With HIV: Dysbiosis, Immune Dysfunction and Therapeutic Perspectives. [PDF]

Rev Med Virol
El Mheddeb S, El Kettani A, Bousfiha AA, Ezzikouri S, Ouladlahsen A.   +4 more
europepmc   +1 more source

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance [PDF]

Journal of Antimicrobial Chemotherapy, 2020
Background Integrase strand transfer inhibitors (INSTIs) are expected to be widely adopted globally, requiring surveillance of resistance emergence and transmission.
Soo-Yon Rhee, Philip L Tzou
exaly   +2 more sources